ALPA.NS
Alpa Laboratories Limited [ALPA.NS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ALPA.NS Stock Summary
Top ALPA.NS Correlated Resources
ALPA.NS
Top 10 Correlated ETFs
ALPA.NS
Top 10 Correlated Stocks
ALPA.NS
In the News
ALPA.NS Financial details
Company Rating
Buy
Market Cap
2.06B
Income
185.94M
Revenue
1.14B
Book val./share
68.08
Cash/share
51.57
Dividend
-
Dividend %
-
Employees
318
Optionable
No
Shortable
Yes
Earnings
12 Feb 2024
P/E
10.86
Forward P/E
-
PEG
3.6
P/S
1.77
P/B
1.41
P/C
1.86
P/FCF
-
Quick Ratio
3.92
Current Ratio
4.38
Debt / Equity
0.01
LT Debt / Equity
-
-
-
EPS (TTM)
8.72
EPS next Y
-
EPS next Q
-
EPS this Y
-10.75%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
73.53%
Revenue last 5Y
3.88%
Revenue Q/Q
27.39%
EPS Q/Q
90.97%
-
-
-
-
SMA20
32.59%
SMA50
26.65%
SMA100
39.75%
Inst Own
-
Inst Trans
-
ROA
10%
ROE
27%
ROC
0.15%
Gross Margin
33%
Oper. Margin
19%
Profit Margin
16%
Payout
-
Shs Outstand
21.04M
Shs Float
7.81M
-
-
-
-
Target Price
-
52W Range
50.3-106.6
52W High
-9.48%
52W Low
+91.9%
RSI
65.97
Rel Volume
0.57
Avg Volume
238.95K
Volume
136.24K
Perf Week
1.16%
Perf Month
27.17%
Perf Quarter
48.99%
Perf Half Y
53.15%
-
-
-
-
Beta
0.675
-
-
Volatility
1.85%, 10.87%
Prev Close
-1.99%
Price
95.95
Change
-2.79%
ALPA.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 36.32 | 40.34 | 45.82 | 52.52 | 43.93 | |
| Net income per share | 0.38 | 0.88 | 3.44 | 6.7 | 6 | |
| Operating cash flow per share | -0.76 | 8.45 | -0.8 | 1.03 | -2.3 | |
| Free cash flow per share | -1.16 | 7.24 | -2.33 | -0.01 | -2.84 | |
| Cash per share | 14.31 | 21.04 | 20.19 | 33.4 | 39.92 | |
| Book value per share | 46.71 | 47.7 | 51.16 | 57.86 | 63.96 | |
| Tangible book value per share | 45.75 | 47.7 | 51.13 | 57.76 | 63.92 | |
| Share holders equity per share | 46.71 | 47.7 | 51.16 | 57.86 | 63.96 | |
| Interest debt per share | 1.02 | 0.24 | 0.1 | 2.83 | 1.2 | |
| Market cap | 567.04M | 291.41M | 757.48M | 1.47B | 1.13B | |
| Enterprise value | 582.22M | 245.78M | 741.38M | 1.51B | 1.07B | |
| P/E ratio | 71.43 | 15.72 | 10.45 | 10.41 | 8.96 | |
| Price to sales ratio | 0.74 | 0.34 | 0.79 | 1.33 | 1.22 | |
| POCF ratio | -35.66 | 1.64 | -44.75 | 67.58 | -23.36 | |
| PFCF ratio | -23.24 | 1.91 | -15.43 | -7.33K | -18.95 | |
| P/B Ratio | 0.58 | 0.29 | 0.7 | 1.2 | 0.84 | |
| PTB ratio | 0.58 | 0.29 | 0.7 | 1.2 | 0.84 | |
| EV to sales | 0.76 | 0.29 | 0.77 | 1.37 | 1.15 | |
| Enterprise value over EBITDA | 8.25 | 2.39 | 6.59 | 11.6 | 6.1 | |
| EV to operating cash flow | -36.62 | 1.38 | -43.8 | 69.55 | -22.02 | |
| EV to free cash flow | -23.86 | 1.61 | -15.1 | -7.55K | -17.86 | |
| Earnings yield | 0.01 | 0.06 | 0.1 | 0.1 | 0.11 | |
| Free cash flow yield | -0.04 | 0.52 | -0.06 | 0 | -0.05 | |
| Debt to equity | 0.02 | 0 | 0 | 0.05 | 0.02 | |
| Debt to assets | 0.01 | 0 | 0 | 0.04 | 0.01 | |
| Net debt to EBITDA | 0.22 | -0.44 | -0.14 | 0.33 | -0.37 | |
| Current ratio | 4.22 | 4.6 | 3.73 | 4.43 | 5.06 | |
| Interest coverage | 0.5 | 49.55 | 283.7 | 84.25 | 30.27 | |
| Income quality | -0.63 | 6.12 | -0.16 | 0.11 | -0.31 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.02 | 0.21 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.53 | -0.14 | 1.9 | -1.01 | 0.23 | |
| Capex to revenue | -0.01 | -0.03 | -0.03 | -0.02 | -0.01 | |
| Capex to depreciation | -0.27 | -0.8 | -2.62 | -1.32 | -0.85 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 19.91 | 30.75 | 62.96 | 93.37 | 92.95 | |
| ROIC | 0 | 0.03 | 0.05 | 0.05 | 0.04 | |
| Return on tangible assets | 0.01 | 0.02 | 0.05 | 0.09 | 0.08 | |
| Graham Net | 23.31 | 14.05 | 26.85 | 37.52 | 44.16 | |
| Working capital | 717.77M | 746.96M | 885.88M | 1.08B | 1.22B | |
| Tangible asset value | 962.55M | 754.2M | 1.08B | 1.22B | 1.34B | |
| Net current asset value | 713.66M | 744.94M | 883.63M | 1.05B | 1.19B | |
| Invested capital | 0.02 | 0 | 0 | 0.05 | 0.02 | |
| Average receivables | 230.22M | 230.84M | 256.32M | 485.98M | 466.14M | |
| Average payables | 132.21M | 134.42M | 192.15M | 198.27M | 149.91M | |
| Average inventory | 138.79M | 132.95M | 145.55M | 160.12M | 140.52M | |
| Days sales outstanding | 220.5 | 0 | 194.07 | 151.7 | 186.75 | |
| Days payables outstanding | 90.66 | 90.46 | 139.4 | 71.59 | 87 | |
| Days of inventory on hand | 96.52 | 82.88 | 93.34 | 74.18 | 73.03 | |
| Receivables turnover | 1.66 | 0 | 1.88 | 2.41 | 1.95 | |
| Payables turnover | 4.03 | 4.04 | 2.62 | 5.1 | 4.2 | |
| Inventory turnover | 3.78 | 4.4 | 3.91 | 4.92 | 5 | |
| ROE | 0.01 | 0.02 | 0.07 | 0.12 | 0.09 | |
| Capex per share | -0.4 | -1.21 | -1.53 | -1.04 | -0.54 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q2
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 6.71 | 12.97 | 12.88 | 12.07 | 15.39 | |
| Net income per share | 0.1 | 2.43 | 2.05 | 1.44 | 2.75 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 36.4 | 0 | 37.1 | 0 | 51.57 | |
| Book value per share | 56.3 | 0 | 59.44 | 0 | 68.08 | |
| Tangible book value per share | 56.25 | 0 | 59.4 | 0 | 68.08 | |
| Share holders equity per share | 56.3 | 0 | 59.44 | 0 | 68.08 | |
| Interest debt per share | 6.93 | 0.03 | 1.03 | 0.01 | 0.75 | |
| Market cap | 1.21B | 1.33B | 1.22B | 1.49B | 1.54B | |
| Enterprise value | 1.32B | 1.33B | 1.15B | 1.49B | 1.53B | |
| P/E ratio | 150.12 | 6.48 | 6.55 | 12.32 | 6.66 | |
| Price to sales ratio | 8.96 | 4.86 | 4.18 | 5.88 | 4.76 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
| P/B Ratio | 1.07 | 0 | 0.91 | 0 | 1.08 | |
| PTB ratio | 1.07 | 0 | 0.91 | 0 | 1.08 | |
| EV to sales | 9.71 | 4.86 | 3.95 | 5.88 | 4.73 | |
| Enterprise value over EBITDA | 205.76 | 25.07 | 13.53 | 45.32 | 24.32 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
| Earnings yield | 0 | 0.04 | 0.04 | 0.02 | 0.04 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.12 | 0 | 0.02 | 0 | 0.01 | |
| Debt to assets | 0.09 | 0 | 0.01 | 0 | 0.01 | |
| Net debt to EBITDA | 16.05 | 0 | -0.76 | 0 | -0.14 | |
| Current ratio | 4.62 | 0 | 5.06 | 0 | 4.38 | |
| Interest coverage | 3.49 | 70.65 | 225.22 | 177.74 | 245.28 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 11.25 | 0 | 52.42 | 0 | 64.9 | |
| ROIC | 0 | 0 | 0.03 | 0 | 0.04 | |
| Return on tangible assets | 0 | 0 | 0.03 | 0 | 0.03 | |
| Graham Net | 34.47 | 0 | 41.04 | 0 | 50.15 | |
| Working capital | 1.1B | 702M | 1.22B | 821.82M | 1.29B | |
| Tangible asset value | 1.14B | 0 | 1.34B | 0 | 1.43B | |
| Net current asset value | 975.11M | 702M | 1.19B | 821.82M | 1.27B | |
| Invested capital | 0.12 | 0 | 0.02 | 0 | 0.01 | |
| Average receivables | 206.26M | 206.26M | 236.48M | 236.48M | 208.71M | |
| Average payables | 84.65M | 84.65M | 75.29M | 75.29M | 124.23M | |
| Average inventory | 79.42M | 79.42M | 63.21M | 63.21M | 63.02M | |
| Days sales outstanding | 274.1 | 0 | 145.98 | 0 | 115.97 | |
| Days payables outstanding | 105 | 0 | 98.2 | 0 | 100.19 | |
| Days of inventory on hand | 98.51 | 0 | 82.44 | 0 | 50.82 | |
| Receivables turnover | 0.33 | 0 | 0.62 | 0 | 0.78 | |
| Payables turnover | 0.86 | 0 | 0.92 | 0 | 0.9 | |
| Inventory turnover | 0.91 | 0 | 1.09 | 0 | 1.77 | |
| ROE | 0 | 0 | 0.03 | 0 | 0.04 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ALPA.NS Frequently Asked Questions
What is Alpa Laboratories Limited stock symbol ?
Alpa Laboratories Limited is a IN stock and trading under the symbol ALPA.NS
What is Alpa Laboratories Limited stock quote today ?
Alpa Laboratories Limited stock price is $95.95 today.
Is Alpa Laboratories Limited stock public?
Yes, Alpa Laboratories Limited is a publicly traded company.
Something similar
Company Profile
- Volume Average 238.95K
- Market Capitalization 2.06B
- Employee 318
- CEO Mr. Mahendra Singh Chawla
- Headquarters Indore,IN
- IPO Date 2007-08-06
-
Website
https://www.alpalabs.in 
Alpa Laboratories Limited engages in manufacturing, marketing, and selling pharmaceutical finished dosage forms in India. It offers ethical, generic, and over the counter products in various finished dosage forms, including injections, tablets, capsules, eye and ear drops, ointments, creams, and gels for human use; and boluses, injections, and intra-mammary infusions for veterinary use. The company also provides drugs in various categories, such as anti-infectives comprising antibacterial, antibiotics, antifungals, antiprotozoals, and antivirals; analgesics; anti-inflammatory drugs; cough and cold drugs; cardiovascular drugs; anti-diabetics; nutritional supplements; psychotropic drugs; and skin care preparations, as well as ear and eye care preparations. It sells its products through distributors, retail chemists, retail pharmacy stores, and hospitals. The company also exports its products to South and Central America, Africa, and Asia, and CIS countries. Alpa Laboratories Limited was founded in 1967 and is based in Indore, India.
